RCS - Deepverge PLC - MicrotoxPD detects 3 COVID variants of concern

DeepvergeAnnouncement

19/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220119:nRSS8679Ya&default-theme=true

RNS Number : 8679Y  Deepverge PLC  19 January 2022

DeepVerge PLC

 

(AIM:DVRG)

 

("DeepVerge" or "the Company")

 

Analysis of Microtox®PD chips coated with Optimer binding agents detect 3
common variants of concern of SARS-CoV-2 virus

 

Modern Water Mobile Services will launch with Alpha, Delta and Omicron
detection capability

 

DeepVerge confirms that analysis to investigate the detection of SARS-CoV-2
virus on Microtox®PD chips coated with Optimers i , binding agents provided
by Aptamer Group plc (AIM:APTA), has detected 3 common variants of concern of
SARS-CoV-2 virus. Modern Water Mobile Services ii  (RNS December 10, 2021),
due to launch later this quarter, will have Compact Microtox®PD units with
the ability to test for all 3 variants to detect and quantify the spready of
COVID-19 in the community.

 

Scientists at the York, UK, Laboratory, have successfully populated the
binding agents on the chips using an anti-SARS-CoV-2 antibody, that was raised
against the Alpha variant. While variation of detection of all 3 variants was
observed, both Delta and Omicron variants had a higher affinity to the Optimer
coated chips than Alpha.

 

The Company believes these results validate the expansion of the York
facilities to accommodate containment level 3 to work on dangerous pathogens,
which include SARS-CoV-2.

 

Gerard Brandon, CEO of DeepVerge plc, commented:

 

"The body of research, protocols and methods created at the York, UK
laboratories, working with the science team at Aptamer Group, and the ability
to work with the real virus, offers confirmation and sets standards that allow
for rapid advances in testing of our partner's binding agents, so that we can
ensure that the latest detection capabilities are available when we roll-out
the Compact Microtox®PD COVID detection units through Modern Water Mobile
Services which was featured on SKY News earlier this month. (video link here
https://vimeo.com/666742992)

 

"The extended scientific community will now have the ability to monitor the
virus in real-time and require testing for new variants of concern."

 

For further information please contact:

 

 DeepVerge plc                                   Gerard Brandon, CEO         +44 (0) 7340 055 648

 SPARK Advisory Partners Limited                 Neil Baldwin/Andrew Emmott  +44 (0) 113 370 8974

 (Nominated Adviser)

 Turner Pope Investments (TPI) Limited (Broker)  Andy Thacker/James Pope     +44 (0) 20 3657 0050

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that
develops and applies AI and IoT technology to analytical instruments for the
analysis and identification of bacteria, virus and toxins. Utilising
artificial intelligent data analytics to scientifically prove the impact of
skincare product claims on skin microbiome for most of the top 20 global
cosmetic company clients and remotely detect and identify in real-time,
dangerous pathogens in wastewater treatment plants, drinking water, rivers,
lakes and reservoirs.

 

About Aptamer Group plc (www.aptamergroup.com)

Aptamer Group develops custom affinity binders through its proprietary
Optimer® platform to enable new approaches in therapeutics, diagnostics and
research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and developers
through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global antibody market is currently worth over
$145bn. Optimer binders are engineered to address many of the issues found
with alternative affinity molecules, such as antibodies, and offer new,
innovative solutions to bioprocessing, diagnostic and pharmaceutical
scientists.

Aptamer Group has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions that support
discovery and development across the Life Sciences.

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

 i 
https://www.londonstockexchange.com/news-article/APTA/optimer-binder-shown-to-detect-omicron-variant/15289220

 ii 
https://www.londonstockexchange.com/news-article/DVRG/compact-microtox-r-pd-launch-scheduled-for-q1-2022/15245142

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAXFPFEAAEFA